TGFB1 and skin basal cell carcinoma: In addition to the biomarkers mentioned in the following section, our group has demonstrated the potential immunosuppressive roles of plasma TGF-β1 and soluble, systemic co-inhibitory immune checkpoint molecules (ICMs) in patients with BCC [103].